Abstract
Objective: Phosphatase and tensin homolog (PTEN) mutations are associated with human endometrial cancers, and PTEN heterozygote(±) mice have a high rate of endometrial neoplasia. The objective of this study was to evaluate an oral mTOR inhibitor (mTOR-I) on the reduction of endometrial hyperplasia in an animal model. Study design: Three groups of 10 female mice were treated from age 20-26 weeks: group A, Pten wild type with mTOR-I; group B, Pten± with placebo; and group C, Pten ± with mTOR-I. Rates of hyperplasia and markers of proliferation and apoptosis were evaluated. Results: Higher grade hyperplasia occurred in a significantly greater percentage of the untreated Pten± group B (80%; 8/10) compared with groups A (0%; 0/10) and C (20%; 2/10; P < .02). The treated Pten± mTOR-I group C also demonstrated significantly increased apoptosis (P < .002) and decreased proliferation index (P < .02) compared with the untreated group B. Conclusion: Oral mTOR inhibition decreases the progression of endometrial hyperplasia in the Pten heterozygote murine model through decreased cell proliferation and increased apoptosis.
Original language | English (US) |
---|---|
Pages (from-to) | 247.e1-247.e5 |
Journal | American journal of obstetrics and gynecology |
Volume | 196 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2007 |
Keywords
- Pten
- RAD001
- endometrial hyperplasia
- mTOR
- murine
ASJC Scopus subject areas
- Obstetrics and Gynecology